Nexavar (Sorafenib)

Sorafenib blocks several key kinases such as RAF, VEGFR‑2, VEGFR‑3, PDGFR‑β, FLT‑3 and c‑KIT. Inhibiting these enzymes interferes with tumor cell proliferation and the formation of new blood vessels, thereby slowing tumor growth and spread.

The specific dosage and schedule of Nexavar are determined by the prescribing physician based on the patient’s condition, weight, liver function and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional.

Nexavar is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect the infant.

To request Nexavar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nexavar belongs to the multi‑kinase inhibitor class, offering a distinct mechanism from monoclonal antibodies or pure VEGF inhibitors. Compared with some alternatives, it targets a broader range of kinases, which can be advantageous in tumors that develop resistance to single‑target agents, though safety profiles differ.

Nexavar tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and store out of reach of children.

Nexavar is taken orally as a tablet, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless the prescriber provides specific instructions.

Serious risks include severe bleeding, hepatic failure, and cardiac ischemia. Patients should be monitored closely for signs of gastrointestinal hemorrhage, liver enzyme elevations, and chest pain or other cardiac symptoms, and treatment should be adjusted or discontinued if these occur.

Nexavar should not be used by patients who are pregnant, breastfeeding, have uncontrolled hypertension, severe hepatic impairment, or a history of significant cardiac ischemia. It is also contraindicated in individuals taking strong CYP3A4 inducers without medical supervision.